BG
BDTX icon

Bellevue Group’s Black Diamond Therapeutics BDTX Stock Holding History

Bellevue Group’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,733,547
Closed -$6.78M – 152
2025
Q2 		$6.78M Hold
2,733,547
– – 0.15% 74
2025
Q1 		$4.24M Sell
2,733,547
-5,784,292
-68% -$12.1M 0.09% 90
2024
Q4 		$18.2M Hold
8,517,839
– – 0.35% 65
2024
Q3 		$37.1M Hold
8,517,839
– – 0.6% 49
2024
Q2 		$39.7M Hold
8,517,839
– – 0.65% 45
2024
Q1 		$43.2M Sell
8,517,839
-18,000
-0.2% -$72.6K 0.66% 48
2023
Q4 		$24M Buy
8,535,839
+400,000
+5% +$938K 0.37% 69
2023
Q3 		$23.3M Hold
8,135,839
– – 0.38% 71
2023
Q2 		$41.1M Buy
8,135,839
+2,740,000
+51% +$5.6M 0.59% 57
2023
Q1 		$10.2M Sell
5,395,839
-5,000
-0.1% -$11.5K 0.15% 94
2022
Q4 		$9.72M Buy
5,400,839
+683,726
+14% +$1.23M 0.13% 100
2022
Q3 		$7.97M Hold
4,717,113
– – 0.11% 102
2022
Q2 		$11.6M Buy
4,717,113
+1,424,113
+43% +$3.31M 0.16% 103
2022
Q1 		$9.12M Sell
3,293,000
-170,000
-5% -$621K 0.11% 108
2021
Q4 		$18.5M Hold
3,463,000
– – 0.19% 103
2021
Q3 		$29.3M Hold
3,463,000
– – 0.3% 91
2021
Q2 		$42.2M Buy
3,463,000
+1,220,000
+54% +$24.1M 0.41% 75
2021
Q1 		$54.4M Buy
2,243,000
+840,000
+60% +$22.7M 0.58% 56
2020
Q4 		$45M Hold
1,403,000
– – 0.52% 56
2020
Q3 		$42.4M Hold
1,403,000
– – 0.59% 49
2020
Q2 		$59.1M Buy
1,403,000
+73,000
+5% +$2.69M 0.84% 32
2020
Q1 		$33.2M Buy
+1,330,000
New +$40.5M 0.64% 44

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bellevue Group's BDTX Position: Q3 2025 in Review

Bellevue Group sold out of Black Diamond Therapeutics (BDTX) in Q3 2025, closing a stake of 2,733,547 shares — an estimated $6.78M sold.

Bellevue Group first reported a position in BDTX in Q1 2020 and held it in 22 quarters. The position peaked at $59.1M in Q2 2020. 91 funds tracked by Wall St. Rank hold BDTX as of Q3 2025.

  • Bellevue Group reported no remaining Black Diamond Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bellevue Group sold 2,733,547 Black Diamond Therapeutics shares in Q3 2025, an estimated $6.78M.
  • Bellevue Group first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 22 quarters.
  • Bellevue Group's Black Diamond Therapeutics position peaked at $59.1M in Q2 2020.
  • 91 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2025.

Based on Bellevue Group's 13F filing for Q3 2025, filed 14 Nov 2025.